Ventyx jumps as oral drug reduces heart disease risk markers in mid-stage trial

Ventyx Biosciences

23/10/2025 10:57

** Shares of drug developer Ventyx Biosciences VTYX.O rise 70% to $6.58 premarket

** Ventyx late on Wednesday said its oral drug VTX3232 cut key inflammation markers tied to heart disease in patients with obesity and cardiovascular risk

** VTYX said its drug lowered hsCRP, an important heart risk marker, by about 80% in the first week

** Levels of IL-6, a protein linked to heart risk, also dropped below the threshold for cardiovascular risk - VTYX

** Co said combination with Novo Nordisk's semaglutide led to further reductions in inflammation markers, but did not boost weight loss

** Up to last close, stock up ~76% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))